(ALAMA) AMA - Ratings and Ratios
Exchange: PA • Country: France • Currency: EUR • Type: Common Stock • ISIN: GB00BNKGZC51
ALAMA: Remote, Assistance, Augmented, Reality,
AMA Corporation Plc (PA:ALAMA) specializes in the development and deployment of advanced remote assistance and video conferencing solutions, operating across 11 countries, including France, the United States, Romania, Germany, the United Kingdom, Hong Kong, China, Canada, Japan, Italy, and Spain. The companys flagship product, the XpertEye suite, integrates augmented reality (AR) technology, dynamic workflow management, and real-time scheduling capabilities, enabling seamless remote collaboration and expertise sharing. Its solutions are compatible with a wide range of devices, including smartphones, smart glasses, tablets, and specialized medical equipment such as microscopes, cameras, endoscopes, and dermatoscopes. The product lineup includes XE aR, XE aR+, XpertEye Proceed, and XpertEye Schedule, all designed to enhance operational efficiency in industries like healthcare, manufacturing, and education. AMA Corporation also offers complementary services such as project management, training, maintenance, technical support, and intellectual property rights management. Founded in 2004 and headquartered in Rennes, France, the company operates as a subsidiary of Guillemot Brothers S.A. and is listed on the Euronext Paris exchange under the ticker symbol ALAMA.
AMA Corporations solutions are particularly valued in the healthcare sector, where its AR-enabled tools facilitate remote medical consultations and training. The integration of XpertEye with medical devices such as endoscopes and dermatoscopes allows healthcare professionals to share high-resolution visuals in real time, improving diagnostic accuracy and enabling remote expert consultations. This has been especially critical in regions with limited access to specialized medical expertise. The companys global reach and cross-industry applicability position it as a key player in the growing remote collaboration and telemedicine markets.
Additional Sources for ALAMA Stock
ALAMA Stock Overview
Market Cap in USD | 16m |
Sector | Healthcare |
Industry | Health Information Services |
GiC Sub-Industry | Health Care Technology |
IPO / Inception |
ALAMA Stock Ratings
Growth 5y | -71.7% |
Fundamental | -25.3% |
Dividend | 0.0% |
Rel. Strength Industry | 11.7 |
Analysts | - |
Fair Price Momentum | 0.18 EUR |
Fair Price DCF | - |
ALAMA Dividends
No Dividends PaidALAMA Growth Ratios
Growth Correlation 3m | 82% |
Growth Correlation 12m | -29.1% |
Growth Correlation 5y | -91.7% |
CAGR 5y | -57.94% |
CAGR/Max DD 5y | -0.59 |
Sharpe Ratio 12m | -0.03 |
Alpha | 16.72 |
Beta | 0.77 |
Volatility | 157.76% |
Current Volume | 55.9k |
Average Volume 20d | 53.6k |
As of March 16, 2025, the stock is trading at EUR 0.25 with a total of 55,903 shares traded.
Over the past week, the price has changed by -9.49%, over one month by +13.24%, over three months by +64.24% and over the past year by +12.73%.
Probably not. Based on ValueRay Fundamental Analyses, AMA (PA:ALAMA) is currently (March 2025) not a good stock to buy. It has a ValueRay Fundamental Rating of -25.34 and therefor a somewhat negative outlook according to the companies health.
Based on ValueRays Analyses, Dividends and Discounted-Cash-Flow, the Fair Value of ALAMA as of March 2025 is 0.18. This means that ALAMA is currently overvalued and has a potential downside of -28%.
AMA has no consensus analysts rating.
According to ValueRays Forecast Model, ALAMA AMA will be worth about 0.2 in March 2026. The stock is currently trading at 0.25. This means that the stock has a potential downside of -20%.
Issuer | Forecast | Upside |
---|---|---|
Wallstreet Target Price | 0.1 | -60% |
Analysts Target Price | - | - |
ValueRay Target Price | 0.2 | -20% |